AHR and neoplasm: The aryl hydrocarbon receptor (AHR) promotes tumor growth, metastasis, genomic instability and chemoresistance, augments immune evasion and has been associated with poorer patient outcome (Deuster et al., 2019; Fauteux et al., 2023; Griffith and Frankel, 2024; Therachiyil et al., 2022).